RESEARCH

Mobilisation of critically ill patients receiving norepinephrine: a retrospective cohort study

Maximilian Lindholz1, Clara M. Schellenberg1, Julius J. Grunow1, Simone Kagerbauer2,3, Annette Milnik4*, Daniel Zickler5, Stefan Angermair6, Anett Reißhauer7, Martin Witzenrath8, Mario Menk1,9, Sebastian Boie9, Felix Balzer9 and Stefan J. Schaller1,2*

Abstract

Background: Mobilisation and exercise intervention in general are safe and feasible in critically ill patients. For patients requiring catecholamines, however, doses of norepinephrine safe for mobilisation in the intensive care unit (ICU) are not defined. This study aimed to describe mobilisation practice in our hospital and identify doses of norepinephrine that allowed a safe mobilisation.

Methods: We conducted a retrospective single-centre cohort study of 16 ICUs at a university hospital in Germany with patients admitted between March 2018 and November 2021. Data were collected from our patient data management system. We analysed the effect of norepinephrine on level (ICU Mobility Scale) and frequency (units per day) of mobilisation, early mobilisation (within 72 h of ICU admission), mortality, and rate of adverse events. Data were extracted from free-text mobilisation entries using supervised machine learning (support vector machine). Statistical analyses were done using (generalised) linear (mixed-effect) models, as well as chi-square tests and ANOVAs.

Results: A total of 12,462 patients were analysed in this study. They received a total of 59,415 mobilisation units. Of these patients, 842 (6.8%) received mobilisation under continuous norepinephrine administration. Norepinephrine administration was negatively associated with the frequency of mobilisation (adjusted difference -0.07 mobilisations per day; 95% CI −0.09, −0.05; p ≤ 0.001) and early mobilisation (adjusted OR 0.83; 95% CI 0.76, 0.90; p ≤ 0.001), while a higher norepinephrine dose corresponded to a lower chance to be mobilised out-of-bed (adjusted OR 0.01; 95% CI 0.00, 0.04; p ≤ 0.001). Mobilisation with norepinephrine did not significantly affect mortality (p > 0.1). Higher compared to lower doses of norepinephrine did not lead to a significant increase in adverse events in our practice (p > 0.1). We identified that mobilisation was safe with up to 0.20 µg/kg/min norepinephrine for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0–1) mobilisation.

Conclusions: Mobilisation with norepinephrine can be done safely when considering the status of the patient and safety guidelines. We demonstrated that safe mobilisation was possible with norepinephrine doses up to 0.20 µg/kg/min for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0–1) mobilisation.

Keywords: Early mobilisation, Early ambulation, Norepinephrine, Adverse events, Supervised machine learning

Introduction

Vasoactive drugs are essential in managing vasodilatory shock, not responsive to volume therapy [1, 2]. They are also administered in cardiogenic and hypovolemic shock [3]. Vasopressors generally bind to specific (e.g. adrenergic) receptors, thereby creating vasoconstriction and
raising the mean arterial pressure (MAP) [2]. Sustaining an adequate MAP is crucial to organ perfusion; however, vasopressors also cause adverse effects, including tachycardia and arrhythmias [1, 2]. For most clinical conditions requiring vasoactive drugs, norepinephrine is the first-line therapy [4].

Vasopressors are an indicator of hemodynamic instability [3] and are perceived as a barrier to starting early mobilisation [5, 6], resulting in less mobilisation [4]. While sufficient mobilisation of patients is a crucial step in rehabilitation in the intensive care unit (ICU) [6–10], too much mobilisation, especially active forms, inherits the potential of harm [11].

There is little to no expert consensus on safe doses of vasoactive drugs in the mobilisation of the critically ill, as well as a lack of quantitative data [12–14]. A systematic review of safety criteria in early mobilisation in 2017 stated that there was no reported safe dose of vasoactive drugs up to which mobilisation can be recommended [14]. A recent systematic review came to the same conclusion and pointed out that data concerning a safe dose of norepinephrine for early mobilisation is inconclusive [13].

This report focuses on norepinephrine since it is the most often used vasopressor [2]. Consequently, this study aims to identify the impact of norepinephrine on mobilisation in general and in a dose-specific manner.

Methods
Study design and data sources
Patient data were extracted from the Charité—Universitätsmedizin Berlin ICU patient data management system (PDMS) to conduct a single-centre retrospective cohort study. Charité extends over different campuses: Campus Charité Mitte (CCM), Campus Virchow-Klinikum (CVK) and Campus Benjamin Franklin (CBF). We included data from 16 intensive care units from March 2018 to November 2021 from the following departments: Department of Anesthesiology and Operative Intensive Care Medicine (CVK, CCM), Department of Anesthesiology and Operative Intensive Care Medicine (CBF), Department of Nephrology and Medical Intensive Care, and Department of Infectious Diseases and Pulmonary Medicine. The analysed database included the following patient details: age; sex; body height and weight; hospital admission and discharge details, name of the ICU(s); daily records of drug administration, drug dosage; diagnoses, comorbidities, and treatment details as documented in the ICD-10 and ICD-OPS Scores; Richmond Agitation-Sedation Scale (RASS) [15], Acute Physiology and Chronic Health Evaluation II (APACHE II) [16], Sequential Organ Failure Assessment score (SOFA Score) [17] as well as free-text mobilisation entries.

This analysis is covered by the approval EA4/084/21 of the ethics committee of the Charité—Universitätsmedizin Berlin from 30.03.2022. According to German regulations, the ethics committee waived the necessity of informed consent due to the retrospective analysis of routine clinical data.

Patient selection
Data were available from 17,913 patients admitted to an ICU in the study period and could uniquely be identified. We excluded patients under 18 years and patients that stayed less than 24 h, as well as patients whose data on age, sex, RASS, or SOFA Scores were missing.

Norepinephrine
To investigate the general impact of norepinephrine on mobilisation practice, patients were classified if they received norepinephrine during their ICU stay at any time (yes/no).

We used the continuous rate given (dosing unit µg/kg/min) for the dose-specific analysis during mobilisation. For the safety analysis, we additionally identified if norepinephrine was applied during a mobilisation unit (yes/no).

We considered doses of >0.2 µg/kg/min as high doses of norepinephrine and between 0.05 and 0.2 µg/kg/min as moderate, below 0.05 as low, comparable to previous research [13, 18]. Mobilisation units were classified accordingly (mobilisation under high/moderate/low norepinephrine).

Covariates and confounder
We selected a priori the following covariates and confounders for risk adjustment and to correct for potential bias based on clinical experience and data availability. Patient-level covariates were age (years), sex (male/female), obesity (ICD-10-Code E66*), COVID-19 (manually extracted from discharge letter as relevant or main diagnosis and positive PCR test or based on ICD-10 Code U07.1), APACHE II and SOFA Score (organ dysfunction) at ICU admission, Elixhauser Comorbidities Index at discharge (labelled according to Quan [19]) and the RASS.

The following therapy details during the stay in the ICU were also used as patient-level covariates: dialysis, ECMO, high flow nasal cannula, non-invasive ventilation, intubation together with invasive mechanical ventilation, and tracheostomy at any time point (yes/no for each variable).

On a hospital level, we used the type of ICU as a potential confounder. If a patient was treated in different types of ICUs (e.g. medical and neurocritical ICU), we used the category “Multiple ICU types”.

The following therapy details during the stay in the ICU were also used as patient-level covariates: dialysis, ECMO, high flow nasal cannula, non-invasive ventilation, intubation together with invasive mechanical ventilation, and tracheostomy at any time point (yes/no for each variable).
For 2,499 cases, we did not have an admission APACHE II score; therefore, we imputed with the mean of the other 9,963 patients (mean = 20.04).

**ICU Mobility Scale (IMS)**

The IMS is an 11-point ordinal scale that assesses the intensity and milestones of mobility in critically ill patients. It has strong interrater reliability and validity [20, 21]. To generate IMS score for each mobilisation unit we extracted free-text mobilisation entries from the mobilisation documentation (typically done by nurses or physical therapists) in our PDMS. Staff members used to some extent individually generated templates for the free-text entries.

IMS scores were generated from the free-text mobilisation entries using a supervised machine learning approach. We were not able to differentiate between a score of 7 or 8 because there is insufficient information on the number of critical care team members assisting in mobilisation in our routine documentation. Although the assistance is mostly carried out by one person, we took a conservative approach and assigned an IMS of 7 in those cases. The highest achieved IMS level of one mobilisation session was used as described [11, 22].

The training and test data were generated by manual labelling 0.8% of the available data: out of a total of 158,272 free-text entries, we randomly selected and blinded 1235 entries; two raters independently labelled these entries with the IMS and additionally identified data, that was wrongly documented (labelled as non-mobilisation entries). We then checked for discrepancies between the ratings of the two raters (5 out of 1235 entries; 0.4%) and decided together on these entries.

The 1235 manually labelled entries were then randomly split into 80% training data and 20% test data. The training data were supplied to a support vector machine (SVM) model and a Naïve Bayes (NB) classifier by using the quanteda R package [23].

Based on the test data, the SVM got an accuracy of 0.91 (95% confidence interval (CI) 0.87–0.94) and outperformed the NB classifier (accuracy 0.67 (95% CI 0.64–0.71)). The Cohen’s kappa of the SVM is 0.89. The “No Information Rate” is 36%, meaning that if you choose the majority class, you will be right at 36%. This indicates that a model with 91% outperforms chance. We used the SVM model to generate the IMS scores for all 158,272 free-text entries. We then removed 17,551 entries labelled as non-mobilisation entries, leaving us with 140,721 IMS scores.

 Afterwards, we used regular expressions to correct for further commonly found mislabels that were not already labelled as non-mobilisation entries by the SVM, resulting in the removal of an additional 3,686 entries and leaving us with a final set of 137,035 mobilisations with IMS scores. 61,422 of these entries took place while the patients were admitted to an ICU and in our study period. As a final quality check, we randomly selected 200 of these SVM-labelled mobilisation entries, blinded them, and again manually labelled them with two independent raters. The concordance rate of the manually labelled and SVM-labelled scores was on average 92%.

The SVM-based automated text-labelling code is available online at github.com [24].

Clinical recommendations distinguish between the two categories of in-bed and out-of-bed mobilisation. For each individual mobilisation unit, we used the SVM-labelled IMS scores and classified them into in-bed or out-of-bed mobilisation. However, there are different definitions in the literature as to which IMS level can be considered in-bed and out-of-bed, with options ranging from IMS 0–1 to IMS 0–3 as in-bed mobilisation [12, 25, 26]. Therefore, we chose the most conservative option (IMS 0–1) as in-bed mobilisation but added a sensitivity analysis using individual IMS levels up to IMS 4.

**Adverse events**

Adverse events were manually extracted from the free-text entries and PDMS during the mobilisation units under norepinephrine, independently by two raters. The agreement between the raters was 100%.

Adverse events (AE) were defined as any unfavourable symptoms or events associated with a mobilisation session, such as mobilisation-induced physiological changes (e.g. hypo- and hypertension, brady-/tachycardia), respiratory symptoms (e.g. dyspnoea, desaturation below 90%), agitation or further minor adverse events like dizziness. Severe adverse events were defined as adverse events that are life-threatening, deadly or lead to permanent disability. These would comprise, for example, cardiac arrest, loss of consciousness and death [8, 13].

**Outcome**

Primary outcomes on mobilisation were:

1. Frequency: average number of mobilisations per day
2. Early mobilisation (i.e. mobilisation in the first 72 h [8, 27, 28]): yes/no
3. Intensity of mobilisation: in-bed (IMS 0–1)/out-of-bed (IMS 2–10)

Secondary outcomes on safety were:

1. Adverse event when mobilised under norepinephrine: yes/no
2. Hospital mortality: yes/no
Statistical analysis
Analyses were done in R (R version 4.1.1 (2021-08-10). Significance testing for group differences was done with chi-square tests for categorical data and Wilcoxon signed-rank test for continuous data using the tableone package [29].

For the main analyses, we applied multivariate linear and mixed models in combination with type III ANOVA using the car package [30] and lme4 package [31].

The effect of norepinephrine (yes/no) on mobilisation frequency was analysed using a general linear model. The effect of norepinephrine (yes/no) on early mobilisation and hospital mortality was analysed by using generalised linear models with and without interaction terms. As a sensitivity analysis, we also analysed the effect of dose and type of mobilisation (in-bed vs. out-of-bed) on the occurrence of adverse events.

For the dose-specific analysis, we assessed the effect of the norepinephrine rate (in µg/kg/min) on the level of mobilisation by using a generalised mixed model with a binomial distribution and subject as a random effect.

To get an unbiased mean and 95th percentile of norepinephrine doses for in-bed and out-of-bed mobilisation, as well as the sensitivity analysis using individual IMS levels till IMS 4, we used the average duration per mobilisation unit and level for each patient. We reported the 95th percentile rather than the maximum value to account for extreme outliers to reduce bias.

To assess the safety of mobilisation under continuous norepinephrine administration, we compared the hospital mortality of the group of patients mobilised during norepinephrine application to those not mobilised during norepinephrine application by using a generalised linear model with a binomial distribution.

Age, sex, obesity, admission Apache-II, admission SOFA Scores, Elixhauser Comorbidities Index, COVID-19, therapy details (ECMO, high flow nasal cannula, non-invasive ventilation, intubation together with invasive mechanical ventilation, tracheostomy) and type of ICU were included as covariates in all models, except the adverse event models, which were unadjusted. In the generalised mixed model, we corrected for the highest absolute RASS on a given day before the mobilisation; in all other models, we included the median absolute RASS. The median absolute score is calculated from daily averages.

Uncorrected estimates are based on the same models without adding any covariates.

We assessed the influence of norepinephrine dosage and type of mobilisation (in-bed vs. out-of-bed) on the occurrence (yes/no) of adverse events using generalised linear models with and without interaction terms. As a sensitivity analysis, we also analysed the effect of dose and individual IMS on the occurrence of adverse events using the same approach. For the individual IMS analysis, we collapsed the data from IMS 5–10 due to small individual sample sizes in the higher IMS groups and used IMS as a linear predictor. Because of the small number of adverse events, we used a Monte Carlo procedure [32] to calculate empirical p values.

A nominal alpha level of 0.05 was considered statistically significant.

Results
A total of 12,462 patients were selected as eligible. These patients received a total number of 59,415 units of mobilisation; 53% of the mobilisation units took place out-of-bed and 47% took place in-bed; 4217 patients (34%) received norepinephrine during their stay, and 8245 (66%) did not receive norepinephrine. Of the 4217 patients, 842 received mobilisation during continuous norepinephrine administration (20% of norepinephrine receiving patients), with a total of 3306 therapy units (12% of therapy units in this group) (Fig. 1).

Patients receiving norepinephrine compared to patients not receiving norepinephrine differed in all included covariates and confounders except for sex and age (Table 1). For differences in comorbidities and diagnosis at admission between the two groups, see Additional file 1: Table S1 and S2.

General impact of norepinephrine on mobilisation
People who received norepinephrine were less likely to be mobilised than to those not receiving norepinephrine (adjusted difference −0.07 mobilisations per day; 95% CI −0.09, −0.05; p ≤ 0.001). They were also less likely to receive early mobilisation (adjusted OR 0.83; 95% CI 0.76, 0.90; p ≤ 0.001).

There was no significant difference in hospital mortality between people receiving norepinephrine and those not receiving norepinephrine during their ICU stay (adjusted OR 1.04; 95% CI 0.91, 1.19; p = 0.58, see Table 2).

Dose-specific impact of norepinephrine on mobilisation
For 842 patients, 3306 mobilisation units were done with continuous norepinephrine administration; 2397 were in-bed mobilisations (IMS 0–1; n = 638 patients) and 909 out-of-bed mobilisations (IMS ≥ 2; n = 395 patients). There were 191 patients, who received both in-bed and out-of-bed mobilisation during their stay.

The mean norepinephrine rate for in-bed mobilisation was 0.12 (SD 0.11) µg/kg/min and for out-of-bed mobilisation 0.07 (SD 0.06) µg/kg/min. The 95th percentile was 0.33 µg/kg/min for in-bed (IMS 0–1) mobilisation and 0.20 µg/kg/min for out-of-bed (IMS ≥ 2) mobilisation. The results of the sensitivity analysis are presented in Table 3 with similar results.

A higher norepinephrine rate was associated with a reduced chance for patients to be mobilised out of bed.
Out of the 3306 mobilisation units, 16% (n = 525) were done with high-dose norepinephrine (> 0.2 µg/kg/min; Table 3), with most of them (90%) being in-bed mobilisation. Moderate doses were administered in 46% of cases (n = 1529), with 75% being in-bed mobilisation. Low doses accounted for 38% of cases (n = 1252), with 62% being in-bed mobilisations (see Table 4). In patients without continuous norepinephrine administration, the rate of in-bed-mobilisation was 45%.

Mortality was not significantly different between patients with and without norepinephrine during mobilisation (adjusted OR 0.96; 95% CI 0.77, 1.19; p = 0.68).

There were a total of 47 adverse events (1%). There was no significant effect of norepinephrine dose on the rate of adverse events (OR 0.2; 95% CI 0.0, 3.8; p > 0.1). There was no significant interaction between dose and group (in-bed, out-of-bed) on the rate of adverse events.
However, there were significantly more adverse events in the group of out-of-bed-mobilisation, regardless of the norepinephrine dose (OR 3.3; 95% CI 1.8, 6.1; p = 0.001, see Table 5).

The adverse events were cardiovascular (hypo-/hypertension, or tachycardia, n = 30), respiratory (e.g. dyspnoea, desaturation below 90% (n = 5)), agitation (n = 3), as well as different minor adverse events (e.g. dizziness) (n = 8). We also registered one severe adverse event in 3306 mobilisation sessions under norepinephrine. The event resulted in the need to resuscitate the patient;
resuscitation was successful. The mobilisation unit was an out-of-bed mobilisation with a moderate norepinephrine dosage (0.14 mcg/kg/min).

In our sensitivity analysis on the rate of adverse events using individual IMS levels up to IMS 4, instead of in-bed versus out-of-bed, we confirmed a missing effect of norepinephrine rate on the occurrence of adverse events (OR: 0.1; 95% CI 0.0, 2.8; \( p > 0.1 \)). Furthermore, there was no significant interaction between IMS level and norepinephrine dose on the rate of adverse events (\( p > 0.1 \)).

**Table 4** Number and percentage of mobilisation units under high/moderate/low norepinephrine, shown separately for in-bed and out-of-bed mobilisation

| Norepinephrine | Out-of-bed mobilisation | In-bed mobilisation | All mobilisations |
|----------------|-------------------------|---------------------|------------------|
| High dose      | 52 (10%)                | 473 (90%)           | 525 (100%)       |
| Moderate dose  | 380 (25%)               | 1149 (75%)          | 1529 (100%)      |
| Low dose       | 477 (38%)               | 775 (62%)           | 1252 (100%)      |
| Total          | 909 (27%)               | 2397 (73%)          | 3306 (100%)      |

**Table 5** Number and percentage of adverse events under high/moderate/low norepinephrine, shown separately for in-bed and out-of-bed mobilisation

|                  | Adverse event | No adverse event | Total  |
|------------------|---------------|------------------|--------|
|                  |               |                  |        |
| High-dose        |               |                  |        |
| Out-of-bed       | 2 (4%)        | 50 (96%)         | 52 (100%) |
| In-bed           | 2 (<1%)       | 471 (>99%)       | 473 (100%) |
| Moderate-dose    |               |                  |        |
| Out-of-bed       | 11 (3%)       | 369 (97%)        | 380 (100%) |
| In-bed           | 11 (1%)       | 1138 (99%)       | 1149 (100%) |
| Low-dose         |               |                  |        |
| Out-of-bed       | 14 (3%)       | 463 (967)        | 477 (100%) |
| In-bed           | 7 (1%)        | 768 (99%)        | 775 (100%) |
| Total            | 47 (1%)       | 3259 (99%)       | 3306 (100%) |

Fig. 2 Histogram of norepinephrine rate (mcg/kg/min) during mobilisation for in-bed (IMS 0–1) and out-of-bed mobilisation (IMS \( \geq 2 \))
However, there were significantly more adverse events at higher IMS levels (OR 1.3; 95% CI 1.1, 1.5; \( p < 0.001 \), see Tables 3 and 5).

**Discussion**

The present study explored the effect of norepinephrine on the mobilisation and safety of these mobilisations. Patients receiving norepinephrine were less likely to be mobilised early, were mobilised less often and were mobilised mostly in-bed only.

The delay in initiation of mobilisation and the reduced frequency of mobilisation is not surprising, with haemodynamic instability being one of the main barriers to the mobilisation of critically ill patients [5, 11, 14]. Higher norepinephrine dosages were associated with decreased mobilisation level for patients who received a continuous norepinephrine application. Mobilisation during norepinephrine administration was predominantly (73%) in-bed, while a minority (45%) of mobilisation was in-bed without noradrenaline administration. The important difference between these mobilisation forms is the verticalisation of the patients. These postural changes are accompanied by haemodynamic changes and strain on the blood pressure regulation of the patients. As an increase in achieved IMS levels also leads to more strain on the circulatory system, an increase in adverse events (mainly being hypotension) would be physiologically understandable [1, 3, 4, 20, 33, 34].

A recent systematic review on early mobilisation with vasoactive drugs found inconsistent recommendations on early mobilisation with vasoactive drugs. The review reported no serious adverse events associated with early mobilisation; adverse events were mainly transient physiological changes (e.g. hypotension) [13]. In our larger cohort, we recorded one severe adverse event; which is low compared to the largest available randomised data available on active forms of mobilisation only [11]. Other than that, we mainly found transient physiological changes (mainly hypotension). There is, to date, no clinical consensus on safe doses of norepinephrine up to which mobilisation can take place [12–14].

Furthermore, there is hardly any quantitative data on adverse events during mobilisation under norepinephrine. A study by Hickmann et al. analysed the mobilisation practices in their hospital, intending to demonstrate that early mobilisation is feasible despite the need for mechanical ventilation, renal replacement therapy, high FiO\(_2\) and vasopressor usage. Their study described 361 mobilisation units with a mean dose of 0.10 µg/kg/min norepinephrine, 19 of which were done with doses of >0.2 µg/kg/min. They reported no severe adverse event and found only transient adverse events in patients mobilised during vasopressors administration [35]. Another way of assessing doses of norepinephrine considered safe is to look at study inclusion criteria. These criteria are based on clinical reasoning rather than quantitative data. Two studies by McWilliams et al. considered doses of >0.2 µg/kg/min to be a contraindication for mobilisation [36, 37]. A study by Sommers et al. considered doses of ≥0.1 µg/kg/min to be a contraindication, as defined in their study protocol [38]. It is essential to understand that Sommers et al. investigated a treadmill system, i.e. out-of-bed active mobilisation only; therefore, the more conservative approach seems reasonable. The largest international mobilisation trial (TEAM RCT) used a combined noradrenaline/adrenaline infusion rate of ≤0.2 µg/kg/min, or if there was an increase by more than 25% in the last 6 h, the dose had to be <0.1 µg/kg/min [22].

Given that in our large cohort, there was no increase in adverse events with a higher dosage, we conclude that mobilisation during norepinephrine administration can be safe. Furthermore, the mortality did not significantly differ in the group of people receiving norepinephrine during mobilisation or not and between people receiving norepinephrine at any time point or not. However, one serious adverse event indicates that mobilisation in critically ill patients needs to be done with care.

Based on our data, we would recommend the 95th percentiles of our observations as dosages up to which safe mobilisation can take place; we recommend 0.2 µg/kg/min norepinephrine for out-of-bed (IMS≥2) and 0.33 µg/kg/min norepinephrine for in-bed (IMS 0–1) mobilisation as proposed dosage thresholds. Our out-of-bed threshold is identical to Yang et al., who developed a safety protocol for mobilisation based on a systematic literature review. They considered norepinephrine doses smaller than 0.2 µg/kg/min and no increase in the past 2 h as a safety criterion for out-of-bed mobilisation [39]. We did not find comparable recommendations for in-bed mobilisation.

**Study limitations**

The study is a single-centre retrospective cohort study. However, Charité – Universitätsmedizin Berlin is the largest university hospital in Europe, with three campuses, and we incorporated data from 16 ICUs of different departments. Information on patients was extracted from routine clinical data. We excluded patients with missing data on our control covariates, except for patients with missing admission APACHE II scores, which we imputed. The IMS in general shows a high interrater reliability [20]. Our supervised machine learning approach also yielded very high accuracy, probably due to semi-structured free-text mobilisation entries; direct documentation of the IMS after each session might
still outperform our approach. Nonetheless, given our large data set and data availability, using a supervised machine learning approach was the most feasible option. Since (serious) adverse events were assessed manually during all mobilisations, the assessment was only feasible if norepinephrine was applied, limiting a comparison with a control group without norepinephrine.

**Conclusions**

Our retrospective study demonstrated that patients receiving norepinephrine during their ICU stay received a lower frequency of mobilisation (mobilisations per day) and less early mobilisation. Higher norepinephrine rates administered during mobilisation were negatively correlated with the level of mobilisation. There was no increase in adverse events with higher norepinephrine doses; however, the rate of adverse events increased with higher IMS levels; this effect was independent of the norepinephrine rate administered. The mortality did not significantly increase for people who received mobilisation under norepinephrine. It can be assumed that doses up to 0.20 mcg/kg/min for out-of-bed mobilisation (IMS ≥ 2) and doses of up to 0.33 mcg/kg/min for in-bed (IMS 0–1) mobilisation seem to be safe.

**Abbreviations**

AE: Adverse event; APACHE II: Acute Physiology and Chronic Health Evaluation II; CBF: Campus Benjamin Franklin; CCM: Campus Charité Mitte; CVK: Campus Virchow-Klinikum; ICU: Intensive care unit; IMS: ICU Mobility Scale; MAP: Mean arterial pressure; NB: Naïve Bayes; PDMs: Patient data management system; RASS: Richmond Agitation-Sedation Scale; SOFA Score: Sequential Organ Failure Assessment Score; SVM: Support vector machine.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-04245-0.

**Author contributions**

ML contributed to the conception and design of the work, as well as acquisition, analysis and interpretation of the data and coding of the R scripts, as well as writing, reviewing and editing of the manuscript. CS contributed to the conception and design of the work, as well as the acquisition of data and reviewing of the manuscript. JG contributed to the conception and design of the work, as well as the interpretation of the data and reviewing the manuscript. AM contributed to the analysis and interpretation of the data and coding of the R scripts, as well as reviewing the manuscript. SB and FB contributed to the acquisition and analysis of the data. SJS contributed to the conception and design of the work, as well as acquisition, analysis and interpretation of the data, as well as reviewing and editing the manuscript. All authors contributed to the critical revision and approved the final manuscript.

**Funding**

Open Access funding enabled and organized by Projekt DEAL. This work was done with institutional funds only.

**Availability of data and materials**

The data analysed are not publicly available due to German privacy regulations. Given a reasonable scientific request, the corresponding author can make the data available via a collaboration agreement.

**Declarations**

**Ethics approval and consent to participate**

This analysis is covered by the approval EA4/084/21 of the ethics committee of the Charité—Universitätsmedizin Berlin from 30.03.2022. According to German regulations, the ethics committee waived the necessity of informed consent due to the retrospective analysis of routine clinical data.

**Consent for publication**

Not applicable.

**Competing interests**

SJS reports grants from Reactive Robotics GmbH (Munich, Germany), grants and non-financial support from STIMIT AG (Biel, Switzerland), Liberare Medical LLC (Crestwood USA), EESC (Geneva, Switzerland), grants, personal fees and non-financial support from Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany), personal fees from Springer Verlag GmbH (Vienna Germany) for educational purposes and Advanz Pharma GmbH (Bielefeld, Germany), non-financial support from National and international societies (and their congress organisers) in the field of anesthesiology and intensive care medicine, outside the submitted work. SJS holds stocks in small amounts from Alphabet Inc., Bayer AG and Siemens AG; these holdings have not affected any decisions regarding his research or this study. MW reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Stiftung, Capnetz Stiftung, International Max Planck Research School, Actelion, Bayer Health Care, Biotest and Boehringer Ingelheim. Personal fees from Actelion, Apatrion, Asta Zeneva, Bayer Health Care, Berlin Chemie, Teva, Biotest, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Novartis, Noixon, Pantherna, Sinoxa, Vaxoilin. MW has the following patents issued EPO 12181535.1: IL-27 for modulation of immune response in acute lung injury Issued (2012), WO/2010/094491: Means for inhibiting the expression of Ang-2 Issued (2010), DE 1020201162499: Camostat/Niclosamide cotreatment in SARS-CoV-2-infected human lung cells Issued (2020/21), PCT/EP2021/075627: New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. FB reports grants from German Federal Ministry of Education and Research, Berlin Institute of Health, German Federal Ministry of Health, Einstein Foundation, Hans Böckler Foundation, Berlin University Alliance. Personal fees from Medtronic, GE and Robert Koch Institut. The other authors declare that they have no competing interests.

**Author details**

1 Department of Anesthesiology and Operative Intensive Care Medicine (CBF), Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. 2 Department of Anesthesiology and Intensive Care Medicine, School of Medicine, Technical University of Munich, Munich, Germany. 3 Department of Anesthesiology and Intensive Care Medicine, Ulm University, Ulm, Germany. 4 Division of Molecular Neuroscience, University of Basel, Basel, Switzerland. 5 Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. 6 Department of Anesthesiology and Operative Intensive Care Medicine (CBF), Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. 7 Department of Physical Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. 8 Department of Infectious Diseases and Pulmonary Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. 9 Institute of Medical Informatics, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany.

Received: 20 September 2022 Accepted: 15 November 2022
Published online: 25 November 2022
References

1. Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive Care Med. 2019;45(11):1503–17.

2. Rhodes A, Evans LE, Ateh JZ, Antonelli M, Benes F, Bernardi M, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2016. Intensive Care Med. 2017;43(3):304–77.

3. Scheeren TWL, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC, et al. Current use of vasopressors in septic shock. Ann Intensive Care. 2019;9(1):20.

4. Annane D, Oumesimes-Besbes L, De Backer D, Du B, Gordon AC, Hernandez G, et al. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018;44(6):833–46.

5. Hermes C, Nydahl P, Blobner M, Dubb R, Filipovic S, Kaltwasser A, et al. Assessment of mobilization capacity in 10 different ICU scenarios by different professions. PLoS ONE. 2020;15(10): e0239853.

6. Iwasyshyn TJ, Hodgson CL. Early mobilisation in ICU is far more than just exercise. Lancet. 2016;388(10052):1351–2.

7. Fuest K, Schaller SJ. Early mobilisation on the intensive care unit: What we know. Med Klin Intensivmed Notfallmed. 2019;114(8):759–64.

8. Schaller SJ, Anstey M, Blobner M, Erichth T, Grabitz SD, Gradwohl-Matis I, et al. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. Lancet. 2016;388(10052):1377–88.

9. Scheffenbichler FT, Teja B, Wongtangman K, Mazwi N, Waak K, Schaller SJ, et al. Effects of the level and duration of mobilization therapy in the surgical ICU on the loss of the ability to live independently: an international prospective cohort study. Crit Care Med. 2021;49(9):e247–57.

10. Paton M, Lane R, Paul E, Cuthbertson GA, Hodgson CL. Mobilization during critical illness: a higher level of mobilization improves health status at 6 months, a secondary analysis of a prospective cohort study. Crit Care Med. 2021;49(9):e860–9.

11. Investigators TS, the ACTG, Hodgson CL, Bailey M, Bellomo R, Brickell K, et al. The ICU mobility scale has construct and predictive validity and is a reliable measure for critically ill adults in the ICU. N Engl J Med. 2022;387:1747–58.

12. Hodgson CL, Stiller K, Needham DM, Tipping CJ, Harrold M, Baldwin CE, et al. Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. Crit Care. 2014;18(6):658.

13. Jacob P, Suresh S, Jadi AE, Babu J, Babu G, Babu K, et al. Effect of early mobilisation on the incidence of nosocomial pneumonia in critically ill patients: a prospective study. J Crit Care. 2021;66(2):356–61.

14. Conceição T, Gonzales AI, Figueiredo F, Vieira DSR, Bundchen DC. Safety criteria to start early mobilization in intensive care units. Systematic review. Rev Bras Ter Intensiva. 2017;29(4):500–19.

15. Ely EW, Truman B, Shintani A, Thomas JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation–Sedation Scale (RASS). JAMA. 2003;289(22):2983–91.

16. Ely EW, Truman B, Shintani A, Thomas JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation Sedation Scale (RASS). JAMA. 2003;289(22):2983–91.

17. Vinson VL, Colon SE, Elia MT, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.

18. Boyd J, Paratz J, Trensted C, Caruana L, McCormack P, Walsh J. When is it safe to exercise mechanically ventilated patients in the intensive care unit? An evaluation of consensus recommendations in a cardiothoracic setting. Heart Lung. 2018;47(2):81–6.

19. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Lu H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(1):1130–7.

20. Hodgson C, Needham D, Haines K, Bailey M, Ward A, Harrold M, et al. Feasibility and inter-rater reliability of the ICU Mobility Scale. Heart Lung. 2014;43(1):19–24.

21. Tipping CJ, Bailey MJ, Bellomo R, Berney S, Buh R, Denehy L, et al. The ICU mobility scale has construct and predictive validity and is responsive. A multicenter observational study. Ann Thorac Surg. 2016;100(6):887–93.

22. Pressnell JJ, Bellomo R, Brickell K, Buh R, Gabbe BJ, Gould DJ, et al. Protocol and statistical analysis plan for the phase 3 randomised controlled trial of Invasively Ventilated Adults with Early Activity and Mobilisation (TEAM III) trial. Crit Care Resusc. 2021;23(3):262–72.

23. Benoit K, Watanabe K, Wang H, Nulty P, Obeng A, Müller S, Matsuo A, quantified: An R package for the quantitative analysis of textual data. J Open Source Softw. 2018;3(30):747.

24. Lindholm M. Support vector machine free text mobilization code. 2022 (updated 11 August 2022). Available from: https://github.com/MaximilianLindholm/ExplainedCodeMobiCovID. Accessed 11 August 2022.

25. Nydahl P, Dubb R, Filipovic S, Hermes C, Jüttner F, Kaltwasser A, et al. Algorithms zur Frühmobilmobilisierung auf Intensivstationen. Medizinische Klinik-Intensivmedizin und Notfallmedizin. 2017;112(2):156–62.

26. Clarissa C, Salisbury L, Rodgers S, Keen S. Early mobilisation in mechanically ventilated patients: a systematic integrative review of definitions and activities. J Intensive Care. 2019;7:3.

27. Hashem MD, Nelliot A, Needham DM. Early mobilization and rehabilitation in the ICU: moving back to the future. Respir Care. 2016;61(7):971–9.

28. Ding N, Zhang Z, Zhang C, Yao L, Yang L, Jiang B, et al. What is the optimum time for initiation of early mobilization in mechanically ventilated patients? A network meta-analysis. PLoS ONE. 2019;14(10): e0223151.

29. Yoshida K, Bartel A. Tableone. Create ‘Table 1′ to Describe Baseline Characteristics with or without Propensity Score Weights. R package version 0.13.2 ed2022.

30. Fox J, Weisberg S. An R companion to applied regression. London: Sage; 2019.

31. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1–48.

32. Nikolova N, Mihaylova N, Tenekedjiev K. Bootstrap tests for mean value differences over fuzzy samples. IFAC-PapersOnLine. 2015;48(24):7–14.

33. Eser I, Khoshshir L, Gunes UY, Demir Y. The effect of different body positions on blood pressure. J Clin Nurs. 2007;16(1):137–40.

34. de Souza PN, Koth J, Ribeiro P, Santos LM, Mendes JM, Aida UV, Pastore L, et al. Effectiveness of a quality improvement strategy with implementation of a specific visual tool to promote ICU early mobilization. Sci Rep. 2022;12(1):17206.

35. Hickmann CE, Castanares-Zapatero D, Bialais E, Dugernier J, Torduer A, Colmant L, et al. Teamwork enables high level of early mobilization in critically ill patients. Ann Intensive Care. 2016;6(1):80.

36. McWilliams D, Atkins G, Hodgson J, Snelson C. The Sara Complifier(R) as an early mobilisation aid for critically ill patients: a prospective and after-study. Aust Crit Care. 2017;30(4):189–95.

37. McWilliams D, Weblin J, Atkins G, Bion J, Williams J, Elliott C, et al. Enhancing rehabilitation of mechanically ventilated patients in the intensive care unit: a quality improvement project. J Crit Care. 2015;30(1):13–8.

38. Sommers J, Engelbert RH, Dettling-Ifenfeldt D, Gosselink R, Spronk PE, Nollet F, et al. Physiotherapy in the intensive care unit: an evidence-based, expert driven, practical statement and rehabilitation recommendations. Clin Rehabil. 2015;29(11):1051–63.

39. Yang R, Zheng Q, Zuo D, Zhang C, Gan X. Safety assessment criteria for early active mobilization in mechanically ventilated ICU subjects. Respir Care. 2021;66(2):307–15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.